Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-β

J Neuroimmunol. 2016 Mar 15:292:93-6. doi: 10.1016/j.jneuroim.2016.01.019. Epub 2016 Jan 30.

Abstract

Bone morphogenic proteins (BMPs) signaling blockade induce neurogenesis and oligodendrogenesis. Differential screening-selected gene aberrative in neuroblastoma (DAN) is a glycoprotein that antagonizes BMPs. We found that DAN levels were higher in CSF compared to serum in all participants. CSF-DAN levels were elevated in RR-and progresssive MS patients compared to controls. Moreover, serum-DAN levels were reduced in those patients, but elevated in IFN-β1a treated patients. The main source of DAN is apparently CNS- resident cells. The enhanced levels of CSF-DAN in MS patients suggest a tendency to induce neurogenesis/oligodendrogenesis in the patients CNS. Our results suggest an unreported mode of action of IFN-β1a.

Keywords: Bone morphogenic proteins; Cerebrospinal fluid; Differential screening-selected gene aberrative in neuroblastoma (DAN); Interferon-β; Multiple sclerosis; Neurogenesis; Oligodendrogenesis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies / cerebrospinal fluid
  • Bone Morphogenetic Proteins / antagonists & inhibitors*
  • Bone Morphogenetic Proteins / immunology
  • Cell Cycle Proteins
  • Cells, Cultured
  • Female
  • Gene Expression Regulation / drug effects*
  • Humans
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Multiple Sclerosis / cerebrospinal fluid*
  • Multiple Sclerosis / drug therapy*
  • Neuroblastoma / cerebrospinal fluid*
  • Neuroblastoma / genetics
  • Proteins / metabolism*
  • Young Adult

Substances

  • Antibodies
  • Bone Morphogenetic Proteins
  • Cell Cycle Proteins
  • NBL1 protein, human
  • Proteins
  • Interferon-beta